FDA approves GSK's BENLYSTA as the first medicine for adult patients with active lupus nephritis in the US
FDA approves GSKs BENLYSTA as the first medicine for adult patients with active lupus nephritis in the US Approval builds on nearly 10 years of experience in lupus News provided by Share this article Share this article LONDON, Dec. 17, 2020 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has approved BENLYSTA (belimumab) for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard therapy. Lupus nephriti...
Source: prnewswire.com